May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Vision-Related Function After Ranibizumab Treatment by Better- or Worse-Seeing Eye: 24 Month Results From MARINA
Author Affiliations & Notes
  • I. J. Suner
    Ophthalmology, Duke Univ Eye Center, Durham, North Carolina
  • N. M. Bressler
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
  • T. S. Chang
    Ophthalmology, Retina Institute of California, Pasadena, California
  • J. T. Fine
    Genentech, Inc., South San Francisco, California
  • C. M. Dolan
    Genentech, Inc., South San Francisco, California
  • J. Ward
    Genentech, Inc., South San Francisco, California
  • Footnotes
    Commercial Relationships I.J. Suner, Bausch & Lomb, C; Carl Zeiss Meditec, C; Genentech, C; OSI Eyetech, C; Pfizer, C; Genentech, Eyetech, Pfizer, Optos, Bausch & Lomb, Carl Zeiss Meditech, R; N.M. Bressler, Bausch & Lomb, F; Acucela, F; Carl Zeiss Meditec, F; Genentech, F; Notal Vision, F; Novartis, F; OSI Eyetech, F; Othera, F; QLT, F; Regeneron, F; TargeGen, F; T.S. Chang, Genentech, C; J.T. Fine, Genentech, Inc, E; C.M. Dolan, Genentech, Inc, E; J. Ward, Genentech, Inc, E.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1808. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. J. Suner, N. M. Bressler, T. S. Chang, J. T. Fine, C. M. Dolan, J. Ward; Vision-Related Function After Ranibizumab Treatment by Better- or Worse-Seeing Eye: 24 Month Results From MARINA. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1808.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To examine the impact of treatment with ranibizumab (LucentisTM)on patient-reported vision-related function (VRF) using theNEI VFQ-25 thru 24 months in a Phase III randomized clinicaltrial (MARINA), with reference to whether the study eye wasthe better- or worse-seeing eye at baseline.


The NEI-VFQ 25 was administered to subjects with neovascularage-related macular degeneration (AMD) at baseline, months 1,2, 3, 6, 9, 12, 18, and 24. A 1:1:1 randomization was carriedout (sham, 0.3mg and 0.5mg). Results were compared between ranibizumab(0.5 mg dose) and sham at 24 months. VRF was assessed by changein mean score from baseline at month 24 for three prespecifiedsubscales (near activities, distance activities, vision-relateddependency). A positive difference represents improved functioning.


Mean changes at 24 months from baseline score were as follows: 



In MARINA, at 24 months vision-related function improved relativeto sham following ranibizumab treatment whether the study eyewas the better- or worse-seeing eye at baseline, although greaterimprovement relative to sham was seen when the study eye wasthe better eye at baseline. These results suggest that the visualacuity improvements reported for MARINA can be associated withimprovements in vision-related function regardless of whetherthe better- or worse-seeing eye is treated.

Clinical Trial: NCT00056836

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • quality of life 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.